Hostname: page-component-7c8c6479df-7qhmt Total loading time: 0 Render date: 2024-03-17T19:39:09.528Z Has data issue: false hasContentIssue false

Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels

Published online by Cambridge University Press:  01 July 2019

Emanuele Felice Osimo*
Affiliation:
Department of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK MRC London Institute of Medical Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, London, UK
Luke James Baxter
Affiliation:
School of Clinical Medicine, University of Cambridge, Cambridge, UK
Glyn Lewis
Affiliation:
Division of Psychiatry, University College London, London, UK
Peter B. Jones
Affiliation:
Department of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK
Golam M. Khandaker
Affiliation:
Department of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK
*
Author for correspondence: Emanuele F. Osimo, E-mail: efo22@cam.ac.uk
Rights & Permissions [Opens in a new window]

Abstract

Background

Peripheral low-grade inflammation in depression is increasingly seen as a therapeutic target. We aimed to establish the prevalence of low-grade inflammation in depression, using different C-reactive protein (CRP) levels, through a systematic literature review and meta-analysis.

Methods

We searched the PubMed database from its inception to July 2018, and selected studies that assessed depression using a validated tool/scale, and allowed the calculation of the proportion of patients with low-grade inflammation (CRP >3 mg/L) or elevated CRP (>1 mg/L).

Results

After quality assessment, 37 studies comprising 13 541 depressed patients and 155 728 controls were included. Based on the meta-analysis of 30 studies, the prevalence of low-grade inflammation (CRP >3 mg/L) in depression was 27% (95% CI 21–34%); this prevalence was not associated with sample source (inpatient, outpatient or population-based), antidepressant treatment, participant age, BMI or ethnicity. Based on the meta-analysis of 17 studies of depression and matched healthy controls, the odds ratio for low-grade inflammation in depression was 1.46 (95% CI 1.22–1.75). The prevalence of elevated CRP (>1 mg/L) in depression was 58% (95% CI 47–69%), and the meta-analytic odds ratio for elevated CRP in depression compared with controls was 1.47 (95% CI 1.18–1.82).

Conclusions

About a quarter of patients with depression show evidence of low-grade inflammation, and over half of patients show mildly elevated CRP levels. There are significant differences in the prevalence of low-grade inflammation between patients and matched healthy controls. These findings suggest that inflammation could be relevant to a large number of patients with depression.

Type
Review Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Cambridge University Press 2019

Introduction

Depression is a common mental illness with a complex aetiology and is one of the leading causes of disability worldwide, affecting around 10–20% of the general population in their lifetime (Lim et al., Reference Lim, Tam, Lu, Ho, Zhang and Ho2018). There is now increasing evidence suggesting an association between depression and inflammation (Goldsmith et al., Reference Goldsmith, Rapaport and Miller2016). For instance, ‘sickness behaviour’ commonly seen following an acute infection, shares many characteristics with depression, such as fatigue, sleep disturbance and decreased motivation (Dantzer et al., Reference Dantzer, O'Connor, Freund, Johnson and Kelley2008); early-life infection and autoimmune diseases are associated with a higher risk of depression in adulthood (Benros et al., Reference Benros, Waltoft, Nordentoft, Østergaard, Eaton, Krogh and Mortensen2013); people with chronic immune-mediated inflammatory diseases such as rheumatoid arthritis exhibit a higher prevalence of depression (Dickens et al., Reference Dickens, McGowan, Clark-Carter and Creed2002). Depression is also associated with other conditions linked with elevated inflammatory markers, such as cardiovascular disease (CVD) (Ridker, Reference Ridker2003).

C-reactive protein (CRP) is a marker of acute phase response which has been used most extensively as a measure of low-grade inflammation in psychiatric (von Känel et al., Reference von Känel, Hepp, Kraemer, Traber, Keel, Mica and Schnyder2007; Fernandes et al., Reference Fernandes, Steiner, Bernstein, Dodd, Pasco, Dean, Nardin, Goncalves and Berk2016) and physical conditions (Visser et al., Reference Visser, Bouter, McQuillan, Wener and Harris1999; Danesh et al., Reference Danesh, Whincup, Walker, Lennon, Thomson, Appleby, Gallimore and Pepys2000). CRP is associated with cardiovascular risk, including myocardial infarction, stroke, sudden cardiovascular death and peripheral vascular disease (Ridker, Reference Ridker2003). Meta-analyses of cross-sectional studies confirm that mean concentrations of circulating CRP and inflammatory cytokines such as interleukin 6 (IL-6) are higher in patients with acute depression compared with controls (Howren et al., Reference Howren, Lamkin and Suls2009; Dowlati et al., Reference Dowlati, Herrmann, Swardfager, Liu, Sham, Reim and Lanctôt2010; Haapakoski et al., Reference Haapakoski, Mathieu, Ebmeier, Alenius and Kivimäki2015; Goldsmith et al., Reference Goldsmith, Rapaport and Miller2016). Population-based longitudinal studies show that higher levels of CRP and IL-6 at baseline are associated with an increased risk of depression in subsequent follow-ups (Gimeno et al., Reference Gimeno, Kivimäki, Brunner, Elovainio, De Vogli, Steptoe, Kumari, Lowe, Rumley and Marmot2009; Wium-Andersen et al., Reference Wium-Andersen, Ørsted, Nielsen and Nordestgaard2013; Khandaker et al., Reference Khandaker, Pearson, Zammit, Lewis and Jones2014; Zalli et al., Reference Zalli, Jovanova, Hoogendijk, Tiemeier and Carvalho2016), suggesting that inflammation could be a cause rather than simply a consequence of the illness.

The association between inflammation and depression is clinically relevant. Poor response to antidepressants is associated with the activation of inflammatory immune responses (Lanquillon et al., Reference Lanquillon, Krieg, Bening-Abu-Shach and Vedder2000; Benedetti et al., Reference Benedetti, Lucca, Brambilla, Colombo and Smeraldi2002; Carvalho et al., Reference Carvalho, Torre, Papadopoulos, Poon, Juruena, Markopoulou, Cleare and Pariante2013; Chamberlain et al., Reference Chamberlain, Cavanagh, de Boer, Mondelli, Jones, Drevets, Cowen, Harrison, Pointon and Pariante2018). It has been reported the mean CRP levels are higher in treatment-resistant compared with treatment-responsive patients with depression (Maes et al., Reference Maes, Bosmans, De Jongh, Kenis, Vandoolaeghe and Neels1997; Sluzewska et al., Reference Sluzewska, Sobieska and Rybakowski1997). Anti-inflammatory treatment has antidepressant effects (Müller et al., Reference Müller, Schwarz, Dehning, Douhe, Cerovecki, Goldstein-Müller, Spellmann, Hetzel, Maino and Kleindienst2006; Köhler et al., Reference Köhler, Benros, Nordentoft, Farkouh, Iyengar, Mors and Krogh2014; Kappelmann et al., Reference Kappelmann, Lewis, Dantzer, Jones and Khandaker2018). Randomised controlled trials (RCTs) indicate that anti-inflammatory drugs are likely to be beneficial particularly for depressed patients who show evidence of inflammation (Raison et al., Reference Raison, Rutherford, Woolwine, Shuo, Schettler, Drake, Haroon and Miller2013; Kappelmann et al., Reference Kappelmann, Lewis, Dantzer, Jones and Khandaker2018). Currently, a number of ongoing RCTs of anti-inflammatory treatments are recruiting specifically depressed patients with elevated CRP levels (e.g. ⩾3 mg/L): NCT02473289; ISRCTN16942542 (Khandaker et al., Reference Khandaker, Oltean, Kaser, Dibben, Ramana, Jadon, Dantzer, Coles, Lewis and Jones2018). Therefore, a better understanding of the prevalence of low-grade inflammation in depression, and of factors associated with inflammation could inform future research and clinical practice.

Inflammation is unlikely to be relevant for all patients with depression (Khandaker et al., Reference Khandaker, Dantzer and Jones2017). While it is established that mean concentrations of peripheral inflammatory markers are higher in depressed patients compared with controls (Howren et al., Reference Howren, Lamkin and Suls2009; Dowlati et al., Reference Dowlati, Herrmann, Swardfager, Liu, Sham, Reim and Lanctôt2010; Haapakoski et al., Reference Haapakoski, Mathieu, Ebmeier, Alenius and Kivimäki2015; Goldsmith et al., Reference Goldsmith, Rapaport and Miller2016), it is unclear what proportion of depressed patients show evidence of low-grade inflammation. Many studies have reported on the prevalence of inflammation in depressed patients using various CRP level thresholds to define inflammation, e.g. >3 or >1 mg/L. These studies have been conducted in different settings and populations, e.g. inpatient, outpatient, population-based (Raison et al., Reference Raison, Rutherford, Woolwine, Shuo, Schettler, Drake, Haroon and Miller2013; Wium-Andersen et al., Reference Wium-Andersen, Ørsted, Nielsen and Nordestgaard2013; Shin et al., Reference Shin, Jung, Kim, Kim and Lim2016). The reported prevalence of inflammation varies widely among these studies; for example, for low-grade inflammation (CRP >3 mg/L) it has been reported to vary between 0% and 60% in existing studies (Ma et al., Reference Ma, Chiriboga, Pagoto, Rosal, Li, Merriam, Hébert, Whited and Ockene2011; Hannestad et al., Reference Hannestad, DellaGioia, Gallezot, Lim, Nabulsi, Esterlis, Pittman, Lee, O'Connor and Pelletier2013). However, as far as we are aware, a systematic review and meta-analysis of the prevalence of low-grade inflammation in patients with depression is currently lacking. While it is likely that the prevalence of low-grade inflammation is higher in patients with depression compared with controls, to our knowledge, no systematic review and meta-analysis has examined the odds ratio for inflammation in depressed patients compared with matched controls.

We conducted a systematic review of existing studies to: (1) quantify the prevalence of low-grade inflammation in patients with depression using meta-analysis; (2) calculate the odds ratio for low-grade inflammation in depressed patients compared with matched healthy controls using meta-analysis; (3) identify sociodemographic and other factors associated with inflammation prevalence in patients with depression using meta-regression analysis. We defined low-grade inflammation as serum CRP levels >3 mg/L. This cut-off has been chosen based on the American Heart Association and Center for Disease Control and Prevention recommendations, which defined CRP levels of >3 mg/L as high (Pearson et al., Reference Pearson, Mensah, Alexander, Anderson, Cannon III, Criqui, Fadl, Fortmann, Hong and Myers2003). In addition, we carried out additional analyses using CRP levels >1 mg/L to define ‘elevated CRP’, and >10 mg/L to define ‘very high CRP’ indicative of current infection. We also carried out a number of sensitivity analyses; for example, meta-analyses using >1 and >3 mg/L thresholds for CRP were repeated using only studies that excluded patients with suspected infection (defined as CRP >10 mg/L); and after excluding poor quality studies.

Methods

Search strategy and study selection

This systematic review has been performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. The search protocol was prospectively published on PROSPERO (see: http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42018106640). The PubMed database was searched for published studies from its inception to 5 of July 2018 using the following keywords: ‘(CRP ORC-reactive proteinORhs-CRPOR hsCRP) OR (C-Reactive Protein[mesh] AND depressi*)’. No language restriction was applied; we only selected studies based on human participants. The electronic search was complemented by hand-searching of meta-analyses and review articles. Abstracts were screened, and full texts of relevant studies were retrieved. Two authors applied the inclusion/exclusion criteria independently and selected the final studies for this review (LB and EFO).

Selection criteria

We included studies that: (1) examined CRP levels in people with depression; (2) assessed depression using clinical criteria (DSM or ICD) or a validated tool (e.g. Hamilton Depression Rating Scale), and reported it as a categorical variable (yes/no); (3) reported CRP levels allowing the calculation of the proportion of ‘inflamed’ patients using cut-offs of either 3, 1 or 10 mg/L. One study used CRP cut-offs of 0.99 and 3.13 mg/L, which was included (Penninx et al., Reference Penninx, Kritchevsky, Yaffe, Newman, Simonsick, Rubin, Ferrucci, Harris and Pahor2003), as these values are very close to the thresholds above. Exclusion criteria were (1) studies reporting measures of inflammation other than CRP, e.g. interleukins or genetic markers; (2) in vitro or animal studies; (3) non-original data, e.g. reviews; (4) studies exclusively based on patients with a medical condition, e.g. cancer.

Recorded variables

The main outcome measure was the proportion of subjects showing elevated CRP in patients and, where reported, in non-depressed controls. We also extracted the following data: author; year of publication; sampling criteria; diagnostic criteria for depression; age of participants; treatment status (antidepressant-free, treatment resistant); ethnicity; matching criteria for patients and controls (if present); study setting and sample source (e.g. community or inpatient); presence of comorbidities. If there were multiple publications from the same data set, we used the study with the largest sample.

Data synthesis

We performed meta-analyses of the prevalence of inflammation in depressed patients using three different CRP cut-offs to define inflammation: >3 (primary), >1 and >10 mg/L. The pooled prevalence of inflammation was calculated using quantitative random-effect meta-analysis, expressed as percentage and 95% CI. The use of random-effect meta-analysis, as opposed to fixed effect, is appropriate when there is heterogeneity between studies. Pooling of studies was performed using the inverse variance method, so that studies with bigger samples were given greater weight. The Clopper–Pearson method was used to compute confidence interval for individual studies, and the logit transformation was used for the transformations of proportions, with a continuity correction of 0.5 in studies with zero cell frequencies. Heterogeneity between studies was measured using the I 2 statistic, which describes the percentage of the variability in effect estimates that is due to heterogeneity. Heterogeneity was tested using Cochrane's Q-Test (Higgins and Thompson, Reference Higgins and Thompson2002). Publication bias was assessed for each group of studies by visual inspection of funnel plots, and tested with an Egger's regression test for funnel plot asymmetry (mixed-effects meta-regression model). P values <0.05, two tailed, were considered statistically significant. We used meta-regression analyses to evaluate the association of inflammation prevalence with age, sex, body mass index (BMI), sample source, proportion of antidepressant-free patients and ethnicity. Seventeen studies reported CRP levels in matched non-depressed controls; these were used to calculate the meta-analytic odds ratio for inflammation in patients with depression v. healthy controls using random-effects estimates for meta-analyses with binary outcome data; pooling of studies was performed using the inverse variance method and with a continuity correction of 0.5 in studies with zero cell frequencies. Study quality was assessed using the Newcastle–Ottawa Scale (Stang, Reference Stang2010). Analyses were repeated with poor quality studies removed. Meta-analyses were carried out using the meta package [version 4.9 (Schwarzer, Reference Schwarzer2007)] in R 3.4 (R Core Team, 2017), and plotted using packages meta and Cairo v1.5 (Urbanek and Horner, Reference Urbanek and Horner2015). Additional information on the methods can be found in the Supplementary Materials.

Results

The literature search yielded 1545 results, out of which 37 studies met the inclusion criteria for meta-analysis (Legros et al., Reference Legros, Mendlewicz and Wybran1985; Penninx et al., Reference Penninx, Kritchevsky, Yaffe, Newman, Simonsick, Rubin, Ferrucci, Harris and Pahor2003; Ladwig et al., Reference Ladwig, Marten-Mittag, Löwel, Döring and Koenig2005; Liukkonen et al., Reference Liukkonen, Silvennoinen-Kassinen, Jokelainen, Räsänen, Leinonen, Meyer-Rochow and Timonen2006; O'brien et al., Reference O'brien, Scott and Dinan2006; Almeida et al., Reference Almeida, Flicker, Norman, Hankey, Vasikaran, van Bockxmeer and Jamrozik2007; Kling et al., Reference Kling, Alesci, Csako, Costello, Luckenbaugh, Bonne, Duncko, Drevets, Manji and Charney2007; Danese et al., Reference Danese, Moffitt, Pariante, Ambler, Poulton and Caspi2008; Nilsson et al., Reference Nilsson, Gustafson and Hultberg2008; Cizza et al., Reference Cizza, Eskandari, Coyle, Krishnamurthy, Wright, Mistry and Csako2009; Harley et al., Reference Harley, Luty, Carter, Mulder and Joyce2010; Ma et al., Reference Ma, Chiriboga, Pagoto, Rosal, Li, Merriam, Hébert, Whited and Ockene2011; Naghashpour et al., Reference Naghashpour, Amani, Nematpour and Haghighizadeh2011; Hannestad et al., Reference Hannestad, DellaGioia, Gallezot, Lim, Nabulsi, Esterlis, Pittman, Lee, O'Connor and Pelletier2013; Raison et al., Reference Raison, Rutherford, Woolwine, Shuo, Schettler, Drake, Haroon and Miller2013; Shanahan et al., Reference Shanahan, Copeland, Worthman, Angold and Costello2013; Park et al., Reference Park, Joo, McIntyre and Kim2014; Uher et al., Reference Uher, Tansey, Dew, Maier, Mors, Hauser, Dernovsek, Henigsberg, Souery and Farmer2014; Wium-Andersen et al., Reference Wium-Andersen, Ørsted and Nordestgaard2014; Courtet et al., Reference Courtet, Jaussent, Genty, Dupuy, Guillaume, Ducasse and Olie2015; Wysokiński et al., Reference Wysokiński, Margulska, Strzelecki and Kłoszewska2015; Cepeda et al., Reference Cepeda, Stang and Makadia2016; Haroon et al., Reference Haroon, Fleischer, Felger, Chen, Woolwine, Patel, Hu and Miller2016; Rapaport et al., Reference Rapaport, Nierenberg, Schettler, Kinkead, Cardoos, Walker and Mischoulon2016; Shin et al., Reference Shin, Jung, Kim, Kim and Lim2016; Ekinci and Ekinci, Reference Ekinci and Ekinci2017; Euteneuer et al., Reference Euteneuer, Dannehl, Del Rey, Engler, Schedlowski and Rief2017; Gallagher et al., Reference Gallagher, Kiss, Lanctot and Herrmann2017; Horsdal et al., Reference Horsdal, Köhler-Forsberg, Benros and Gasse2017; Jha et al., Reference Jha, Minhajuddin, Gadad, Greer, Grannemann, Soyombo, Mayes, Rush and Trivedi2017; Cáceda et al., Reference Cáceda, Griffin and Delgado2018; Chamberlain et al., Reference Chamberlain, Cavanagh, de Boer, Mondelli, Jones, Drevets, Cowen, Harrison, Pointon and Pariante2018; Felger et al., Reference Felger, Haroon, Patel, Goldsmith, Wommack, Woolwine, Le, Feinberg, Tansey and Miller2018; Osimo et al., Reference Osimo, Cardinal, Jones and Khandaker2018b; Porcu et al., Reference Porcu, Urbano, Verri, Barbosa, Baracat, Vargas, Machado, Pescim and Nunes2018; Shibata et al., Reference Shibata, Ohara, Yoshida, Hata, Mukai, Kawano, Kanba, Kitazono and Ninomiya2018; Wei et al., Reference Wei, Du, Wu, Fu and Xia2018). Please see Supplementary Fig. S1 for the PRISMA diagram of study selection, and Table 1 for details of the included studies.

Table 1. Characteristics of studies included in the meta-analysis

a CES-D, The Center for Epidemiologic Studies Depression Scale; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th. Edition; GDS, Geriatric Depression Scale; BDI, Beck's Depression Inventory; SCID, Structured Clinical Interview for DSM; CAPA, The Child and Adolescent Psychiatric Assessment; ICD, World Health Organisation International Classification of Diseases; PHQ9, Patient Health Questionnaire-9; HAMD-17, Hamilton Depression Rating Scale (HDRS).

b Studies evaluated using the Newcastle–Ottawa Scale (see Supplementary methods and Table S1), then converted to Agency for Healthcare Research and Quality – AHRQ – standards (good, fair and poor) using these thresholds:

  • Good quality: ⩾75% in Selection domain AND ⩾50% in Comparability domain AND ⩾50% in Outcome domain.

  • Fair quality: 50% in Selection domain AND ⩾50% in Comparability domain AND ⩾50% in Outcome domain.

  • Poor quality: ⩽50% in Selection domain OR 0% in Comparability domain OR ⩽50% in Outcome domain.

c Not available.

Prevalence of low-grade inflammation (CRP >3 mg/L) in depressed patients

Results based on all available studies

Thirty studies comprising 11 813 patients with depression were used for this analysis. The meta-analytic pooled prevalence of low-grade inflammation in depressed patients was 27% (95% CI 21–34%); see Fig. 1. There was evidence of heterogeneity among studies (I 2 = 97.7%; 95% CI 97.3–98.1%; Cochrane's Q = 1264; p = <0.01). Further analyses after grouping studies by setting showed that the prevalence of inflammation in inpatient samples (N = 1265) was 30% (95% CI 21–42%; I 2 = 91.9%; Cochrane's Q = 62); in outpatient samples (N = 3528) it was 29% (95% CI 19–43%; I 2 = 95.9%; Cochrane's Q = 338); and in population-based samples (N = 7020) it was 24% (95% CI 17–34%; I 2 = 98.3%; Cochrane's Q = 483).

Fig. 1. Prevalence of low-grade inflammation (CRP >3 mg/L) in depressed patients.

Analyses excluding poor quality studies or cases with past depression

A sensitivity analysis excluding six poor quality studies, comprising 8778 patients, showed that the prevalence of inflammation was 27% (95% CI 22–33%); Supplementary Table S1 and Fig. S2. There was evidence of heterogeneity (I 2 = 96.4%; 95% CI 95.5–97.1%; Cochrane's Q = 644; p = <0.01). A sensitivity analysis excluding two studies where depression was not active in all patients, comprising 11 763 patients, showed that the prevalence of inflammation was 26% (95% CI 20–34%); Supplementary Fig. S3. There was evidence of heterogeneity (I 2 = 97.9%; 95% CI 97.4–98.2%; Cochrane's Q = 1261; p = <0.01).

Analysis after excluding cases of suspected infection (CRP >10 mg/L)

Nine studies reported the prevalence of low-grade inflammation after excluding participants with suspected infection, defined as CRP >10 mg/L. A separate meta-analysis based on these studies, comprising 6948 patients, showed that the prevalence of inflammation was 16% (95% CI 8–32%); Supplementary Fig. S4. There was evidence of heterogeneity (I 2 = 98.8%; 95% CI 98.5–99.1%; Cochrane's Q = 675; p = <0.01).

Association between prevalence of low-grade inflammation (CRP >3 mg/L) and characteristics of depressed patients

Meta-regression was used on 19 studies comprising 7858 patients to test the association between the prevalence of inflammation and the proportion of patients who were antidepressant-free at the time of study. There was no association between these factors (estimate: −0.007; z = −1.03; p = 0.30). Similarly, sex, age, non-White ethnicity, BMI and sample source (inpatient, outpatient or population-based) were not associated with the prevalence of inflammation (see Supplementary Results).

Assessment of publication bias

A funnel plot of the 30 studies assessing the prevalence of low-grade inflammation (CRP >3 mg/L) in depression visually appeared symmetrical (Supplementary Fig. S5). Egger's regression test for funnel plot asymmetry was non-significant (t = −1.3; df = 28; p = 0.21), suggesting there was no evidence of publication bias.

Odds ratio for low-grade inflammation (>3 mg/L) in depressed patients

Seventeen studies reported the prevalence of inflammation in 7761 depressed patients and 155 728 matched non-depressed controls (see Supplementary Table S2 for matching details). The meta-analytic OR for inflammation in depressed patients compared with matched controls was 1.46 (95% CI 1.22–1.75; p < 0.0001); see Fig. 2. There was evidence of heterogeneity (I 2 = 71.9%; 95% CI 54.3–82.7%; Cochrane's Q = 57; p = <0.01).

Fig. 2. Odds ratio for low-grade inflammation (CRP >3 mg/L) in depressed patients compared with matched controls.

Based on the same studies, we meta-analysed the prevalence of inflammation in depressed patients and matched non-depressed controls separately. The prevalence of inflammation in controls was 16% (95% CI 11–23%) and that in depressed patients was 24% (95% CI 17–34%); see Supplementary Figs S6 and S7.

We carried out sensitivity analyses based on five available studies of depressed patients and matched healthy controls that excluded subjects with very high levels of CRP (>10 mg/L). These studies, comprising 3868 patients and 63 212 controls, showed that the prevalence of inflammation in controls was 10% (95% CI 3–26%) and that in patients it was 13% (95% CI 4–36%); see Supplementary Figs S8 and S9. Based on these studies, the meta-analytic OR for inflammation in depressed patients compared with matched controls was 1.44 (95% CI 0.80–2.61; p = 0.23); see Supplementary Fig. S10.

A sensitivity analysis excluding poor quality studies, comprising 5045 patients and 105 372 controls, showed that the meta-analytic OR for inflammation in depressed patients compared with matched controls was 1.56 (95% CI 1.29–1.88; p < 0.0001); see Supplementary Table S1 and Fig. S11. A further sensitivity analysis only including studies that matched patients and controls by BMI, comprising 2624 patients and 79 887 controls, showed that the meta-analytic OR for inflammation in depressed patients compared with matched controls was 1.59 (95% CI 1.08–2.34; p = 0.02); see Supplementary Fig. S12. Finally, a sensitivity analysis excluding studies where depression was not active in all patients showed that the meta-analytic OR for inflammation in depressed patients compared with matched controls was 1.47 (95% CI 1.22–1.75; p = 0.02); see Supplementary Fig. S13.

Prevalence of elevated CRP levels (>1 mg/L) in depressed patients

Results based on all available studies

Twenty-five studies comprising 8887 patients with depression were used for this analysis. The meta-analytic pooled prevalence of elevated CRP >1 mg/L in depressed patients was 58% (95% CI 47–69%); see Fig. 3. There was evidence of heterogeneity (I 2 = 98.7%; 95% CI 98.5–98.9%; Cochrane's Q = 1862; p = <0.01). Further analyses after grouping studies by setting showed that the prevalence of elevated CRP in inpatient samples (N = 1023) was 56% (95% CI 46–66%; I 2 = 81.8%; Cochrane's Q = 22); in outpatient samples (N = 697) was 59% (95% CI 50–67%; I 2 = 74.9%; Cochrane's Q = 40); and in population-based samples (N = 7167) was 57% (95% CI 34–77%; I 2 = 99.5%; Cochrane's Q = 1774).

Fig. 3. Prevalence of elevated CRP (>1 mg/L) in depressed patients.

Analyses excluding poor quality studies or cases with past depression

A sensitivity analysis excluding four poor quality studies showed that the prevalence of elevated CRP >1 mg/L in depressed patients was 57% (95% CI 43–69%); Supplementary Table S1 and Fig. S14. There was evidence of heterogeneity (I 2 = 98.9%; 95% CI 98.7–99.1%; Cochrane's Q = 1858; p = <0.01). A further sensitivity analysis excluding studies where depression was not active in all patients showed that the prevalence of elevated CRP in depressed patients was 58% (95% CI 45–69%); Supplementary Fig. S15. There was evidence of heterogeneity (I 2 = 98.8%; 95% CI 98.6–99.0%; Cochrane's Q = 1861; p = <0.01).

Analysis after excluding cases of suspected infection (CRP>10 mg/L)

Eight studies also reported the prevalence of elevated CRP after excluding participants with suspected infection, defined as CRP >10 mg/L. A separate meta-analysis based on these studies, comprising 4456 patients that excluded patients with CRP levels >10 mg/L showed that the prevalence of elevated CRP >1 mg/L was 50% (95% CI 29–72%); see Supplementary Fig. S16 There was evidence of heterogeneity (I 2 = 99.1%; 95% CI 98.9–99.3%; Cochrane's Q = 816; p = <0.01).

Association between prevalence of elevated CRP levels (>1 mg/L) and characteristics of depressed patients

Meta-regression analyses did not find any significant association of elevated CRP with sex, age, BMI, non-White ethnicity, being antidepressant-free or sample source (see Supplementary Results).

Assessment of publication bias

A funnel plot of the 25 studies assessing the prevalence of elevated CRP in depression appeared visually symmetrical. Egger's regression test for funnel plot asymmetry was non-significant (t = −0.43; df = 23; p = 0.67), suggesting there was no evidence of publication bias (Supplementary Fig. S17).

Odds ratio for elevated CRP levels (>1 mg/L) in depressed patients

Fifteen studies reported the prevalence of elevated CRP >1 mg/L in 5177 depressed patients and 106 682 matched non-depressed controls (see Supplementary Table S2 for matching details). The meta-analytic OR for elevated CRP in depressed patients compared with matched controls was 1.47 (95% CI 1.18–1.82; p = 0.0005); see Fig. 4. There was evidence of heterogeneity (I 2 = 75.6%; 95% CI 59.8–85.2%; Cochrane's Q = 57; p = <0.01).

Fig. 4. Odds ratio for elevated CRP (>1 mg/L) in depressed patients compared with matched controls.

Based on the same studies, we meta-analysed the prevalence of elevated CRP in depressed patients and matched non-depressed controls separately. The prevalence of elevated CRP >1 mg/L in controls was 44% (95% CI 26–65%) and that in depressed patients was 59% (95% CI 41–75%); see Supplementary Figs S18 and S19.

A sensitivity analysis based on 12 studies after excluding poor quality studies showed that the meta-analytic OR for elevated CRP in depressed patients compared with matched controls was 1.51 (95% CI 1.22–1.88; p = 0.0002); see Supplementary Table S1 and Fig. S20. A sensitivity analysis only including the nine studies that matched the patients and controls by BMI showed that the meta-analytic OR for elevated CRP >1 mg/L in depressed patients compared with matched controls was 1.52 (95% CI 1.12–2.07; p = 0.01); see Supplementary Fig. S21. A further sensitivity analysis excluding studies where depression was not active in all patients showed that the meta-analytic OR for elevated CRP in depressed patients compared with healthy controls was 1.47 (95% CI 1.19–1.81; p = 0.0003); see Supplementary Fig. S22. Finally, a sensitivity analysis of the four studies excluding subjects with very high levels of CRP (>10 mg/L) showed that the meta-analytic OR for elevated CRP in depressed patients compared with healthy controls was 1.29 (95% CI 0.38–4.30; p = 0.68); see Supplementary Fig. S23.

Very high CRP levels (>10 mg/L) in depressed patients and healthy controls

We used data from four available studies comprising 3926 patients and 62 748 matched healthy controls. The meta-analytic pooled prevalence of very high CRP in depressed patients matched to healthy controls was 3% (95% CI 1–11%); in the same studies, prevalence of very high CRP in healthy controls matched to depressed patients was 1% (95% CI 0–4%); the meta-analytic OR for very high CRP in depressed patients compared with matched controls was 1.52 (95% CI 1.13–2.05; p = 0.006); see Supplementary Figs S24–26.

Discussion

To our knowledge, this is one of the first systematic reviews and meta-analyses of the prevalence of low-grade inflammation in patients with depression. We report that a notable proportion of depressed patients show evidence of inflammation. Approximately one in four patients with depression show CRP levels >3 mg/L, a widely used threshold to define low-grade inflammation in the literature. The prevalence is unaltered after excluding poor quality studies, or after excluding studies where depression was not active. After excluding patients with suspected infection, the prevalence of low-grade inflammation is about one in six. We also report that approximately three patients out of five have mildly elevated CRP (>1 mg/L). The prevalence is unaltered after excluding poor quality studies, or after excluding studies where depression was not active. After excluding patients with suspected infection, the prevalence of elevated CRP is one in two. Meta-regression analyses show that the prevalence of inflammation in depression is not associated with sex, age, BMI, ethnicity or sample source.

Using matched non-depressed controls, we quantified the odds ratios of low-grade inflammation and of elevated CRP in depressed patients. We report that the proportion of patients with depression showing elevated inflammatory markers as compared to matched healthy controls is remarkably stable: the ORs were 1.46 for CRP levels >3 mg/L, 1.47 for CRP levels >1 mg/L and 1.52 for CRP levels >10 mg/L. There was no evidence of publication bias within the included studies, but there was evidence of heterogeneity in all analyses.

Knowing inflammation levels in patients with depression could be important for several reasons, particularly for predicting the risk of physical illness and for predicting response to psychiatric treatment. Inflammation is a potentially causal risk factor for CVD (Pearson et al., Reference Pearson, Mensah, Alexander, Anderson, Cannon III, Criqui, Fadl, Fortmann, Hong and Myers2003), because CVD is associated with circulating IL-6 and CRP levels (Pradhan et al., Reference Pradhan, Manson, Rossouw, Siscovick, Mouton, Rifai, Wallace, Jackson, Pettinger and Ridker2002; Danesh et al., Reference Danesh, Wheeler, Hirschfield, Eda, Eiriksdottir, Rumley, Lowe, Pepys and Gudnason2004; Danesh et al., Reference Danesh, Kaptoge, Mann, Sarwar, Wood, Angleman, Wensley, Higgins, Lennon and Eiriksdottir2008) and with genetic variants regulating levels/activity of IL-6 (IL6R Genetics Consortium Emerging Risk Factors Collaboration, 2012; Interleukin-6 Receptor Mendelian Randomisation Analysis Consortium, 2012). Depression is co-morbid with CVD (Hare et al., Reference Hare, Toukhsati, Johansson and Jaarsma2013). Depression increases the risk of incident CVD, and is a marker of poor prognosis after myocardial infarction (Nicholson et al., Reference Nicholson, Kuper and Hemingway2006). Inflammation could be a shared mechanism for these conditions. Using Mendelian randomisation analysis of the UK Biobank sample, we previously found that out of all cardiovascular risk factors, IL-6, CRP and triglycerides are likely to be causally linked with depression (Khandaker et al., Reference Khandaker, Zuber, Rees, Carvalho, Mason, Foley, Gkatzionis, Jones and Burgess2019). Therefore, cardiovascular risk screening in depressed patients who show evidence of inflammation could be useful. Our work suggests that such screening will be relevant for about a quarter of patients with depression.

We focussed on CRP levels as our preferred measure of inflammation because it has been widely used in different fields of medicine to measure inflammation, and standardised cut-offs for CRP exist in the literature. The American Heart Association and Center for Disease Control and Prevention have proposed clear CRP thresholds as indicators of inflammation levels (<1 = ‘low’, 1–3 = ‘medium’, >3 mg/L = ‘high’) (Pearson et al., Reference Pearson, Mensah, Alexander, Anderson, Cannon III, Criqui, Fadl, Fortmann, Hong and Myers2003). Our findings are consistent with previous meta-analyses reporting higher mean concentrations of CRP, IL-6 and other inflammatory markers in depressed patients compared with controls (Howren et al., Reference Howren, Lamkin and Suls2009; Dowlati et al., Reference Dowlati, Herrmann, Swardfager, Liu, Sham, Reim and Lanctôt2010; Haapakoski et al., Reference Haapakoski, Mathieu, Ebmeier, Alenius and Kivimäki2015; Goldsmith et al., Reference Goldsmith, Rapaport and Miller2016). Our study adds to the literature by providing information on the proportion of depressed patients who have evidence of inflammation.

In addition to depression and CVD, inflammation is associated with other physical and psychiatric disorders including diabetes mellitus (Pradhan et al., Reference Pradhan, Manson, Rifai, Buring and Ridker2001), schizophrenia (Miller et al., Reference Miller, Buckley, Seabolt, Mellor and Kirkpatrick2011; Khandaker et al., Reference Khandaker, Cousins, Deakin, Lennox, Yolken and Jones2015) and dementias (Schmidt et al., Reference Schmidt, Schmidt, Curb, Masaki, White and Launer2002). Inflammation is also an important predictor of increased all-cause mortality (Zacho et al., Reference Zacho, Tybjærg-Hansen and Nordestgaard2010; Sung et al., Reference Sung, Ryu, Chang, Byrne and Kim2014; Li et al., Reference Li, Zhong, Cheng, Zhao, Zhang, Hong, Wan, He and Wang2017). Therefore, routine CRP screening in patients with depression, and identification and treatment of the cause of inflammation could improve overall health-related mortality and morbidity. Public health interventions aimed at reducing inflammation could improve mortality and morbidity associated with a number of conditions.

It is unlikely that anti-inflammatory drugs will be useful for all patients with depression (Khandaker et al., Reference Khandaker, Dantzer and Jones2017). Measurement of CRP levels could inform patient selection in RCTs of anti-inflammatory drugs for depression. We are aware of two studies that are testing novel anti-inflammatory drugs such as monoclonal antibodies (mAb) against the IL-6/IL-6R pathway. One study testing the efficacy and safety of sirukumab (anti-IL-6 mAb) for depression has completed recruitment (NCT02473289). We are conducting an RCT of tocilizumab (anti-IL-6R mAb) for patients with depression (Khandaker et al., Reference Khandaker, Oltean, Kaser, Dibben, Ramana, Jadon, Dantzer, Coles, Lewis and Jones2018). Both of these studies are based on patients with CRP levels ⩾3 mg/L. Secondary analysis of existing RCTs suggests mAb against specific inflammatory cytokines, such as IL-6/IL-6R, could be helpful for depression (Sun et al., Reference Sun, Wang, Salvadore, Hsu, Curran, Casper, Vermeulen, Kent, Singh and Drevets2017; Kappelmann et al., Reference Kappelmann, Lewis, Dantzer, Jones and Khandaker2018). However, definitive efficacy trials need to be completed before anti-inflammatory drugs can be considered in psychiatric clinical practice. Our findings suggest that up to a quarter of depressed patients show signs of low-grade inflammation. Future studies should explore the potential causes for this, and also whether depressed patients with higher CRP levels may benefit from anti-inflammatory treatments.

Studies included in this review varied on setting, country and analytic methods, and the proportion of depressed patients with elevated CRP (>3 mg/L) in these studies ranged between 0% and 60%. In our analyses, the prevalence of inflammation was not associated with participant age and sex, antidepressant treatment, ethnicity or source of sample. This is the case despite the samples spanning all age groups [median age: 42.2 years; inter-quartile range (IQR): 37–59]. Both sexes were well represented (median proportion of males: 36%, IQR: 17–41%). The samples comprised both antidepressant-free and treated populations (antidepressant-free = 6 studies; 100% treated = 3 studies; mixed populations = 10 studies). Included studies covered samples collected from inpatient (N = 6), outpatient (N = 15) and general population (N = 9). One reason for not detecting an association between inflammation and sociodemographic factors could be that a number of studies matched patients and controls on these factors.

The meta-analytic prevalence of low-grade inflammation (CRP >3 mg/L) in non-depressed controls seen in our analysis is 16%, which is lower than the prevalence of inflammation reported in some general population studies. For instance, Ford et al. (Reference Ford, Giles, Mokdad and Myers2004) reported the prevalence of low-grade inflammation to be about 25% in a sample of adult US women. Khera et al. (Reference Khera, McGuire, Murphy, Stanek, Das, Vongpatanasin, Wians, Grundy and de Lemos2005) reported the prevalence of CRP >3 mg/L to be >30% in US adult males and females. One reason for these high prevalence reports in general population samples could be that these studies include both healthy and diseased individuals including those with chronic inflammatory physical illness. Therefore, for a more accurate comparison of the prevalence of inflammation between depressed cases and healthy controls, we have used studies that included cases matched to healthy controls for the calculation of odds ratios. In our results, the stability of the odds ratios for elevated CRP in depressed patients compared with healthy controls across different CRP thresholds (ORs = 1.46 for CRP levels >3 mg/L; OR = 1.47 for CRP levels >1 mg/L; and OR = 1.52 for CRP levels >10 mg/L) provides confidence that patients are more likely to have evidence of inflammation than healthy controls. Furthermore, excluding patients with very high levels of inflammation did not significantly affect the odds ratio for low-grade inflammation (>3 mg/L) in depressed subjects (OR = 1.44).

Strengths of this work include the systematic nature of the literature search, which identified a large number of relevant studies comprising 13 541 patients and 155 728 controls from different countries and settings, and spanning diverse ethnic and age groups. The methods were laid out prospectively and published on PROSPERO (Osimo et al., Reference Osimo, Baxter, Jones and Khandaker2018a). We assessed the studies for quality using the validated Newcastle–Ottawa Scale (Stang, Reference Stang2010). We conducted multiple sensitivity analyses to examine the robustness of the findings. There was no evidence of publication bias, suggesting that we covered a range of results spanning the whole expected distribution of means.

Limitations of this work include sample heterogeneity: the studies we included used different methods to assess depression (albeit a valid method was required for inclusion), and samples were recruited from different sources making it difficult to test the association between the prevalence of inflammation and depression severity. However, we have reported meta-analytic results separately by sample source (community, inpatient, etc.), which could be taken as an indirect indicator of depression severity. Inflammation prevalence did not differ much by sample source. However, due to the lack of comparable data on depression severity, we could not assess this directly. Study setting and sample characteristics could account for some of the observed heterogeneity. We used random-effects meta-analyses in order to take care of inter-study variability. Another limitation is that we were not able to account for comorbidities, partly because for some studies this information was not reported. By design we have focused on dichotomous measure of inflammation, so we cannot comment on the distributions of continuous CRP values in patients/controls; these have been subject to previous meta-analyses reporting higher mean levels of CRP in depression compared with controls (Howren et al., Reference Howren, Lamkin and Suls2009; Dowlati et al., Reference Dowlati, Herrmann, Swardfager, Liu, Sham, Reim and Lanctôt2010; Haapakoski et al., Reference Haapakoski, Mathieu, Ebmeier, Alenius and Kivimäki2015; Goldsmith et al., Reference Goldsmith, Rapaport and Miller2016).

In summary, this systematic review and meta-analysis provides a robust estimate of the prevalence of low-grade inflammation in depressed patients, which is about one in four. We also report that depressed patients are about 50% more likely to have evidence of inflammation as compared to matched non-depressed controls. These findings are relevant for future treatment studies of anti-inflammatory drugs and for clinical practice, particularly for predicting response to antidepressants and for predicting co-morbid, immune-related physical illness, such as CVD.

Supplementary material

The supplementary material for this article can be found at https://doi.org/10.1017/S0033291719001454

Author ORCIDs

Emanuele Felice Osimo, 0000-0001-6239-5691

Acknowledgements

Dr Khandaker acknowledges grant support from the Wellcome Trust (201486/Z/16/Z), UK Medical Research Council (MC_PC_17213), and MQ: Transforming Mental Health (MQDS17/40). PBJ acknowledges grant support from the Wellcome Trust (095844/Z/11/Z & 088869/Z/09/Z) and NIHR [RP-PG-0616-20003 and the Collaboration for Leadership in Applied Health Research & Care (CLAHRC) East of England]. The funding bodies had no role in design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication.

Financial disclosures

The authors have no conflict of interests or financial disclosures to declare.

References

Almeida, OP, Flicker, L, Norman, P, Hankey, GJ, Vasikaran, S, van Bockxmeer, FM and Jamrozik, K (2007) Association of cardiovascular risk factors and disease with depression in later life. The American Journal of Geriatric Psychiatry 15, 506513.Google Scholar
Benedetti, F, Lucca, A, Brambilla, F, Colombo, C and Smeraldi, E (2002) Interleukine-6 serum levels correlate with response to antidepressant sleep deprivation and sleep phase advance. Progress in Neuro-psychopharmacology and Biological Psychiatry 26, 11671170.Google Scholar
Benros, ME, Waltoft, BL, Nordentoft, M, Østergaard, SD, Eaton, WW, Krogh, J and Mortensen, PB (2013) Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry 70, 812820.Google Scholar
Cáceda, R, Griffin, WST and Delgado, PL (2018) A probe in the connection between inflammation, cognition and suicide. Journal of Psychopharmacology 32, 482488.Google Scholar
Carvalho, L, Torre, J, Papadopoulos, A, Poon, L, Juruena, M, Markopoulou, K, Cleare, A and Pariante, C (2013) Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. Journal of Affective Disorders 148, 136140.Google Scholar
Cepeda, MS, Stang, P and Makadia, R (2016) Depression is associated with high levels of C-reactive protein and low levels of fractional exhaled nitric oxide: results from the 2007–2012 national health and nutrition examination surveys. The Journal of Clinical Psychiatry 77, 16661671.Google Scholar
Chamberlain, SR, Cavanagh, J, de Boer, P, Mondelli, V, Jones, DN, Drevets, WC, Cowen, PJ, Harrison, NA, Pointon, L and Pariante, CM (2018) Treatment-resistant depression and peripheral C-reactive protein. The British Journal of Psychiatry, 19.Google Scholar
Cizza, G, Eskandari, F, Coyle, M, Krishnamurthy, P, Wright, E, Mistry, S and Csako, G (2009) Plasma CRP levels in premenopausal women with major depression: a 12-month controlled study. Hormone and Metabolic Research 41, 641.Google Scholar
Courtet, P, Jaussent, I, Genty, C, Dupuy, A, Guillaume, S, Ducasse, D and Olie, E (2015) Increased CRP levels may be a trait marker of suicidal attempt. European Neuropsychopharmacology 25, 18241831.Google Scholar
Danese, A, Moffitt, TE, Pariante, CM, Ambler, A, Poulton, R and Caspi, A (2008) Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Archives of General Psychiatry 65, 409415.Google Scholar
Danesh, J, Whincup, P, Walker, M, Lennon, L, Thomson, A, Appleby, P, Gallimore, JR and Pepys, MB (2000) Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. British Medical Journal 321, 199204.Google Scholar
Danesh, J, Wheeler, JG, Hirschfield, GM, Eda, S, Eiriksdottir, G, Rumley, A, Lowe, GD, Pepys, MB and Gudnason, V (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. New England Journal of Medicine 350, 13871397.Google Scholar
Danesh, J, Kaptoge, S, Mann, AG, Sarwar, N, Wood, A, Angleman, SB, Wensley, F, Higgins, JP, Lennon, L and Eiriksdottir, G (2008) Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Medicine 5, e78.Google Scholar
Dantzer, R, O'Connor, JC, Freund, GG, Johnson, RW and Kelley, KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience 9, 46.Google Scholar
Dickens, C, McGowan, L, Clark-Carter, D and Creed, F (2002) Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosomatic Medicine 64, 5260.Google Scholar
Dowlati, Y, Herrmann, N, Swardfager, W, Liu, H, Sham, L, Reim, EK and Lanctôt, KL (2010) A meta-analysis of cytokines in major depression. Biological Psychiatry 67, 446457.Google Scholar
Ekinci, O and Ekinci, A (2017) The connections among suicidal behavior, lipid profile and low-grade inflammation in patients with major depressive disorder: a specific relationship with the neutrophil-to-lymphocyte ratio. Nordic Journal of Psychiatry 71, 574580.Google Scholar
Euteneuer, F, Dannehl, K, Del Rey, A, Engler, H, Schedlowski, M and Rief, W (2017) Immunological effects of behavioral activation with exercise in major depression: an exploratory randomized controlled trial. Translational Psychiatry 7, e1132.Google Scholar
Feighner, JP, Robins, E, Guze, SB, Woodruff, RA, Winokur, G and Munoz, R (1972) Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry 26, 5763.Google Scholar
Felger, JC, Haroon, E, Patel, TA, Goldsmith, DR, Wommack, EC, Woolwine, BJ, Le, N-A, Feinberg, R, Tansey, MG and Miller, AH (2018) What does plasma CRP tell us about peripheral and central inflammation in depression? Molecular Psychiatry, epub ahead of printGoogle Scholar
Fernandes, B, Steiner, J, Bernstein, H, Dodd, S, Pasco, J, Dean, O, Nardin, P, Goncalves, C and Berk, M (2016) C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Molecular Psychiatry 21, 554.Google Scholar
Ford, ES, Giles, WH, Mokdad, AH and Myers, GL (2004) Distribution and correlates of C-reactive protein concentrations among adult US women. Clinical Chemistry 50, 574581.Google Scholar
Gallagher, D, Kiss, A, Lanctot, K and Herrmann, N (2017) Depression with inflammation: longitudinal analysis of a proposed depressive subtype in community dwelling older adults. International Journal of Geriatric Psychiatry 32, e18e24.Google Scholar
Gimeno, D, Kivimäki, M, Brunner, EJ, Elovainio, M, De Vogli, R, Steptoe, A, Kumari, M, Lowe, GD, Rumley, A and Marmot, MG (2009) Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychological Medicine 39, 413423.Google Scholar
Goldsmith, D, Rapaport, M and Miller, B (2016) A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Molecular Psychiatry 21, 16961709.Google Scholar
Haapakoski, R, Mathieu, J, Ebmeier, KP, Alenius, H and Kivimäki, M (2015) Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain, Behavior, and Immunity 49, 206215.Google Scholar
Hannestad, J, DellaGioia, N, Gallezot, J-D, Lim, K, Nabulsi, N, Esterlis, I, Pittman, B, Lee, J-Y, O'Connor, KC and Pelletier, D (2013) The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [11C] PBR28 PET study. Brain, Behavior, and Immunity 33, 131138.Google Scholar
Hare, DL, Toukhsati, SR, Johansson, P and Jaarsma, T (2013) Depression and cardiovascular disease: a clinical review. European Heart Journal 35, 13651372.Google Scholar
Harley, J, Luty, S, Carter, J, Mulder, R and Joyce, P (2010) Elevated C-reactive protein in depression: a predictor of good long-term outcome with antidepressants and poor outcome with psychotherapy. Journal of Psychopharmacology 24, 625.Google Scholar
Haroon, E, Fleischer, C, Felger, J, Chen, X, Woolwine, B, Patel, T, Hu, X and Miller, A (2016) Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression. Molecular Psychiatry 21, 1351.Google Scholar
Higgins, J and Thompson, SG (2002) Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 21, 15391558.Google Scholar
Horsdal, H, Köhler-Forsberg, O, Benros, M and Gasse, C (2017) C-reactive protein and white blood cell levels in schizophrenia, bipolar disorders and depression-associations with mortality and psychiatric outcomes: a population-based study. European Psychiatry 44, 164172.Google Scholar
Howren, MB, Lamkin, DM and Suls, J (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic Medicine 71, 171186.Google Scholar
IL6R Genetics Consortium Emerging Risk Factors Collaboration (2012) Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. The Lancet 379, 12051213.Google Scholar
Interleukin-6 Receptor Mendelian Randomisation Analysis Consortium (2012) The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. The Lancet 379, 12141224.Google Scholar
Jha, MK, Minhajuddin, A, Gadad, BS, Greer, T, Grannemann, B, Soyombo, A, Mayes, TL, Rush, AJ and Trivedi, MH (2017) Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. Psychoneuroendocrinology 78, 105113.Google Scholar
Kappelmann, N, Lewis, G, Dantzer, R, Jones, PB and Khandaker, GM (2018) Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Molecular Psychiatry 23, 335.Google Scholar
Khandaker, GM, Pearson, RM, Zammit, S, Lewis, G and Jones, PB (2014) Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry 71, 11211128.Google Scholar
Khandaker, GM, Cousins, L, Deakin, J, Lennox, BR, Yolken, R and Jones, PB (2015) Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. The Lancet Psychiatry 2, 258270.Google Scholar
Khandaker, GM, Dantzer, R and Jones, PB (2017) Immunopsychiatry: important facts. Psychological Medicine 47, 22292237.Google Scholar
Khandaker, GM, Oltean, BP, Kaser, M, Dibben, CR, Ramana, R, Jadon, DR, Dantzer, R, Coles, AJ, Lewis, G and Jones, PB (2018) Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation. BMJ Open 8, e025333.Google Scholar
Khandaker, GM, Zuber, V, Rees, JMB, Carvalho, L, Mason, AM, Foley, CN, Gkatzionis, A, Jones, PB and Burgess, S (2019) Shared mechanism between depression and coronary heart disease: findings from Mendelian randomization analysis of a large UK population-based cohort. Molecular Psychiatry, epub ahead of print.Google Scholar
Khera, A, McGuire, DK, Murphy, SA, Stanek, HG, Das, SR, Vongpatanasin, W, Wians, FH, Grundy, SM and de Lemos, JA (2005) Race and gender differences in C-reactive protein levels. Journal of the American College of Cardiology 46, 464469.Google Scholar
Kling, MA, Alesci, S, Csako, G, Costello, R, Luckenbaugh, DA, Bonne, O, Duncko, R, Drevets, WC, Manji, HK and Charney, DS (2007) Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biological Psychiatry 62, 309313.Google Scholar
Köhler, O, Benros, ME, Nordentoft, M, Farkouh, ME, Iyengar, RL, Mors, O and Krogh, J (2014) Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71, 13811391.Google Scholar
Ladwig, K-H, Marten-Mittag, B, Löwel, H, Döring, A and Koenig, W (2005) C-reactive protein, depressed mood, and the prediction of coronary heart disease in initially healthy men: results from the MONICA–KORA Augsburg Cohort Study 1984–1998. European Heart Journal 26, 25372542.Google Scholar
Lanquillon, S, Krieg, J-C, Bening-Abu-Shach, U and Vedder, H (2000) Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22, 370379.Google Scholar
Legros, S, Mendlewicz, J and Wybran, J (1985) Immunoglobulins, autoantibodies and other serum protein fractions in psychiatric disorders. European Archives of Psychiatry and Neurological Sciences 235, 911.Google Scholar
Li, Y, Zhong, X, Cheng, G, Zhao, C, Zhang, L, Hong, Y, Wan, Q, He, R and Wang, Z (2017) Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: a meta-analysis. Atherosclerosis 259, 7582.Google Scholar
Lim, GY, Tam, WW, Lu, Y, Ho, CS, Zhang, MW and Ho, RC (2018) Prevalence of depression in the community from 30 countries between 1994 and 2014. Scientific Reports 8, 2861.Google Scholar
Liukkonen, T, Silvennoinen-Kassinen, S, Jokelainen, J, Räsänen, P, Leinonen, M, Meyer-Rochow, VB and Timonen, M (2006) The association between C-reactive protein levels and depression: results from the northern Finland 1966 birth cohort study. Biological Psychiatry 60, 825830.Google Scholar
Ma, Y, Chiriboga, DE, Pagoto, SL, Rosal, MC, Li, W, Merriam, PA, Hébert, JR, Whited, MC and Ockene, IS (2011) Association between depression and C-reactive protein. Cardiology Research and Practice 2011, 286509.Google Scholar
Maes, M, Bosmans, E, De Jongh, R, Kenis, G, Vandoolaeghe, E and Neels, H (1997) Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9, 853858.Google Scholar
Miller, BJ, Buckley, P, Seabolt, W, Mellor, A and Kirkpatrick, B (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biological Psychiatry 70, 663671.Google Scholar
Müller, N, Schwarz, M, Dehning, S, Douhe, A, Cerovecki, A, Goldstein-Müller, B, Spellmann, I, Hetzel, G, Maino, K and Kleindienst, N (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Molecular Psychiatry 11, 680.Google Scholar
Naghashpour, M, Amani, R, Nematpour, S and Haghighizadeh, MH (2011) Riboflavin status and its association with serum hs-CRP levels among clinical nurses with depression. Journal of the American College of Nutrition 30, 340347.Google Scholar
Nicholson, A, Kuper, H and Hemingway, H (2006) Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. European Heart Journal 27, 27632774.Google Scholar
Nilsson, K, Gustafson, L and Hultberg, B (2008) C-reactive protein: vascular risk marker in elderly patients with mental illness. Dementia and Geriatric Cognitive Disorders 26, 251256.Google Scholar
O'brien, SM, Scott, LV and Dinan, TG (2006) Antidepressant therapy and C-reactive protein levels. The British Journal of Psychiatry 188, 449452.Google Scholar
Osimo, E, Baxter, L, Jones, P and Khandaker, G (2018 a) Prevalence of low-grade inflammation in depression: a review and meta-analysis of CRP data. PROSPERO. Available at http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018106640.Google Scholar
Osimo, EF, Cardinal, RN, Jones, PB and Khandaker, GM (2018 b) Prevalence and correlates of low-grade systemic inflammation in adult psychiatric inpatients: an electronic health record-based study. Psychoneuroendocrinology 91, 226234.Google Scholar
Park, S, Joo, YH, McIntyre, RS and Kim, B (2014) Metabolic syndrome and elevated C-reactive protein levels in elderly patients with newly diagnosed depression. Psychosomatics 55, 640649.Google Scholar
Parloff, MB, Kelman, HC and Frank, JD (1954) Comfort, effectiveness, and self-awareness as criteria of improvement in psychotherapy. American Journal of Psychiatry 111, 343352.Google Scholar
Pearson, TA, Mensah, GA, Alexander, RW, Anderson, JL, Cannon III, RO, Criqui, M, Fadl, YY, Fortmann, SP, Hong, Y and Myers, GL (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499511.Google Scholar
Penninx, BW, Kritchevsky, SB, Yaffe, K, Newman, AB, Simonsick, EM, Rubin, S, Ferrucci, L, Harris, T and Pahor, M (2003) Inflammatory markers and depressed mood in older persons: results from the health, aging and body composition study. Biological Psychiatry 54, 566572.Google Scholar
Porcu, M, Urbano, MR, Verri, WA Jr, Barbosa, DS, Baracat, M, Vargas, HO, Machado, RCBR, Pescim, RR and Nunes, SOV (2018) Effects of adjunctive N-acetylcysteine on depressive symptoms: modulation by baseline high-sensitivity C-reactive protein. Psychiatry Research 263, 268274.Google Scholar
Pradhan, AD, Manson, JE, Rifai, N, Buring, JE and Ridker, PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286, 327334.Google Scholar
Pradhan, AD, Manson, JE, Rossouw, JE, Siscovick, DS, Mouton, CP, Rifai, N, Wallace, RB, Jackson, RD, Pettinger, MB and Ridker, PM (2002) Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 288, 980987.Google Scholar
Raison, CL, Rutherford, RE, Woolwine, BJ, Shuo, C, Schettler, P, Drake, DF, Haroon, E and Miller, AH (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70, 3141.Google Scholar
Rapaport, MH, Nierenberg, AA, Schettler, PJ, Kinkead, B, Cardoos, A, Walker, R and Mischoulon, D (2016) Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Molecular Psychiatry 21, 71.Google Scholar
R Core Team (2017). R: A Language and Environment for Statistical Computing [Software]. Vienna, Austria: R Foundation for Statistical Computing.Google Scholar
Ridker, PM (2003) Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107, 363369.Google Scholar
Schmidt, R, Schmidt, H, Curb, JD, Masaki, K, White, LR and Launer, LJ (2002) Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Annals of Neurology 52, 168174.Google Scholar
Schwarzer, G (2007) Meta’: an R package for meta-analysis: R news, 7, 4045.Google Scholar
Shanahan, L, Copeland, WE, Worthman, CM, Angold, A and Costello, EJ (2013) Children with both asthma and depression are at risk for heightened inflammation. The Journal of Pediatrics 163, 14431447.Google Scholar
Shibata, M, Ohara, T, Yoshida, D, Hata, J, Mukai, N, Kawano, H, Kanba, S, Kitazono, T and Ninomiya, T (2018) Association between the ratio of serum arachidonic acid to eicosapentaenoic acid and the presence of depressive symptoms in a general Japanese population: the Hisayama Study. Journal of Affective Disorders 237, 7379.Google Scholar
Shin, Y-C, Jung, C-H, Kim, H-J, Kim, E-J and Lim, S-W (2016) The associations among vitamin D deficiency, C-reactive protein, and depressive symptoms. Journal of Psychosomatic Research 90, 98104.Google Scholar
Sluzewska, A, Sobieska, M and Rybakowski, J (1997) Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology 35, 123127.Google Scholar
Stang, A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European Journal of Epidemiology 25, 603605.Google Scholar
Sun, Y, Wang, D, Salvadore, G, Hsu, B, Curran, M, Casper, C, Vermeulen, J, Kent, JM, Singh, J and Drevets, WC (2017) The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease. Brain, Behavior, and Immunity 66, 156164.Google Scholar
Sung, K-C, Ryu, S, Chang, Y, Byrne, CD and Kim, SH (2014) C-reactive protein and risk of cardiovascular and all-cause mortality in 268 803 East Asians. European Heart Journal 35, 18091816.Google Scholar
Uher, R, Tansey, KE, Dew, T, Maier, W, Mors, O, Hauser, J, Dernovsek, MZ, Henigsberg, N, Souery, D and Farmer, A (2014) An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. American Journal of Psychiatry 171, 12781286.Google Scholar
Urbanek, S and Horner, J (2015) Cairo: R graphics device using Cairo graphics library for creating high-quality bitmap (PNG, JPEG, TIFF), vector (PDF, SVG, PostScript) and display (X11 and Win32) output [Software]. CRAN. R-project.Google Scholar
Visser, M, Bouter, LM, McQuillan, GM, Wener, MH and Harris, TB (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA 282, 21312135.Google Scholar
von Känel, R, Hepp, U, Kraemer, B, Traber, R, Keel, M, Mica, L and Schnyder, U (2007) Evidence for low-grade systemic proinflammatory activity in patients with posttraumatic stress disorder. Journal of Psychiatric Research 41, 744752.Google Scholar
von Zerssen, D and Cording, C (1978) The measurement of change in endogenous affective disorders. Archiv für Psychiatrie und Nervenkrankheiten 226, 95112.Google Scholar
Wei, L, Du, Y, Wu, W, Fu, X and Xia, Q (2018) Elevation of plasma neutrophil gelatinase-associated lipocalin (NGAL) levels in schizophrenia patients. Journal of Affective Disorders 226, 307312.Google Scholar
Wium-Andersen, MK, Ørsted, DD, Nielsen, SF and Nordestgaard, BG (2013) Elevated C-reactive protein levels, psychological distress, and depression in 73 131 individuals. JAMA Psychiatry 70, 176184.Google Scholar
Wium-Andersen, MK, Ørsted, DD and Nordestgaard, BG (2014) Elevated C-reactive protein, depression, somatic diseases, and all-cause mortality: a Mendelian randomization study. Biological Psychiatry 76, 249257.Google Scholar
Wysokiński, A, Margulska, A, Strzelecki, D and Kłoszewska, I (2015) Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder. Nordic Journal of Psychiatry 69, 346353.Google Scholar
Zacho, J, Tybjærg-Hansen, A and Nordestgaard, BG (2010) C-reactive protein and all-cause mortality – the Copenhagen city heart study. European Heart Journal 31, 16241632.Google Scholar
Zalli, A, Jovanova, O, Hoogendijk, W, Tiemeier, H and Carvalho, L (2016) Low-grade inflammation predicts persistence of depressive symptoms. Psychopharmacology 233, 16691678.Google Scholar
Figure 0

Table 1. Characteristics of studies included in the meta-analysis

Figure 1

Fig. 1. Prevalence of low-grade inflammation (CRP >3 mg/L) in depressed patients.

Figure 2

Fig. 2. Odds ratio for low-grade inflammation (CRP >3 mg/L) in depressed patients compared with matched controls.

Figure 3

Fig. 3. Prevalence of elevated CRP (>1 mg/L) in depressed patients.

Figure 4

Fig. 4. Odds ratio for elevated CRP (>1 mg/L) in depressed patients compared with matched controls.

Supplementary material: File

Osimo et al. supplementary material

Osimo et al. supplementary material 1

Download Osimo et al. supplementary material(File)
File 6.5 MB